Antitumor Drug
ChemicalBook > CAS DataBase List > Lenalidomide

Lenalidomide

Antitumor Drug
Product Name
Lenalidomide
CAS No.
191732-72-6
Chemical Name
Lenalidomide
Synonyms
enaL;idomide;CC-5013;Revlimi;Revlimid;Lenalidomid;enalidomide;Lenadoamide;lenalidomide;To the amine
CBNumber
CB3855432
Molecular Formula
C13H13N3O3
Formula Weight
259.26
MOL File
191732-72-6.mol
More
Less

Lenalidomide Property

Melting point:
265-268 °C
Boiling point:
614.0±55.0 °C(Predicted)
Density 
1.460±0.06 g/cm3(Predicted)
storage temp. 
2-8°C
pka
10.75±0.40(Predicted)
CAS DataBase Reference
191732-72-6(CAS DataBase Reference)
More
Less

Safety

Risk Statements 
20/21/22
Safety Statements 
36/37
HazardClass 
IRRITANT
HS Code 
29339900
Hazardous Substances Data
191732-72-6(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
14643
Product name
Lenalidomide
Purity
≥98%
Packaging
100mg
Price
$125
Updated
2021/12/16
Cayman Chemical
Product number
14643
Product name
Lenalidomide
Purity
≥98%
Packaging
1g
Price
$313
Updated
2021/12/16
Cayman Chemical
Product number
14643
Product name
Lenalidomide
Purity
≥98%
Packaging
500mg
Price
$188
Updated
2021/03/22
Tocris
Product number
6305
Product name
Lenalidomide
Purity
≥98%(HPLC)
Packaging
100
Price
$49
Updated
2021/12/16
TRC
Product number
L328000
Product name
Lenalidomide
Packaging
5mg
Price
$85
Updated
2021/12/16
More
Less

Lenalidomide Chemical Properties,Usage,Production

Antitumor Drug

Lenalidomide is a kind of antitumor drugs that developed by American biological pharmaceutical companies. Its chemical structure is similar with thalidomide. It has many functions such as anti-tumor, immune regulation and anti-angiogenesis. It can inhibit the secretion of inflammatory cytokines, and increase the secretion of peripheral blood mononuclear anti-inflammatory cytokines. Vitro tests show that lenalidomide can inhibit the hyperplasia of some cell lines such as namalwa cell. It can inhibit the growth of patients’ multiple myeloma cells and MM1S cell. In addition, lenalidomide also can inhibit the expression of oxidase-2 (COX-2), but it has no effect on COX-1. Two multicenter randomized double-blind placebo-controlled clinical studies evaluate the safety and curative effect of lenalidomide that is used for multiple myeloma. The primary efficacy end point of the studies is time to progression (TTP). The interim analysis shows that TTP of the combination group is significantly superior to dexamethasone group. Recent clinical research results show that lenalidomide not only has curative effect on treating MDS and MM, but also on treating myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized amyloidosis and systemic bone marrow fibrosis disease with marrow unripe.
Lenalidomide is a new derivative of thalidomide. But its teratogenic toxicity has not found. Its effectiveness is 100 times stronger than thalidomide. According to the result of three clinical trials, lenalidomide is the most effective drug in the treatment of multiple myeloma. More than half of patients can prolong survival time to more than 3 years after taking the drug. In addition, it is also the only effective drugs to treat myelodysplastic syndrome (MDS). Clinical results find that 64% of the patients with MDS need not use blood transfusion after treated by lenalidomide.
In December 2005, the US Food and Drug Administration (FDA) approved lenalidomide to be used in the treatment of myelodysplastic syndrome (MDS).
In March 2006, the FDA approved lenalidomide that was produced by American Celgene Biological Pharmaceutical Companies to be used in the treatment of multiple myeloma (MM).
On September 23, 2011, the European Medicines Agency (EMA) released information that they have confirmed that the benefits of lenalidomide(trade name: Revlimid) to be used in the treatment of patients group that was approved outweighed the risks. Meanwhile they warned the doctor the risk of the drug to cause new cancer cases. Lenalidomide has been used with dexamethasone to treat adult patients with multiple myeloma that has received at least one treatment. Three new studies show that the incidence of new cancer will be increased in the patients with newly diagnosed multiple myeloma treated by lenalidomide and other combined treatment increased incidence of cancer.
The above information is edited by the Chemicalbook Geqian.

Description

Lenalidomide is a derivative of thalidomide differing in the presence of an amino moiety in the 4-position and removal of one of the carbonyls of the phthaloyl ring. This derivative evolved from a structural-based effort to eliminate the adverse effects (somnolence, neuropathy, and teratogenicity) of thalidomide while maintaining or enhancing the appealing attributes. While the mechanism of action remains to be fully identified, lenalidomide inhibits TNF-a production in stimulated monocytes. In addition to inhibiting TNF-a secretion, the production of other pro-inflammatory cytokines is blocked. Complimentary to inhibition of pro-inflammatory cytokines, lenalidomide also increases the secretion of antiinflammatory cytokines, such as IL-10. Furthermore, lenalidomide inhibits secretion of angiogenic cytokines, VEGF and bFGF. Due to its immunomodulatory and antiangiogenic properties, lenalidomide has the potential for a wide spectrum of therapeutic applications. While other indications are under evaluation, lenalidomide has initially been launched for the treatment of myelodysplastic syndromes (MDS), a set of hematologic disorders that affect the bone marrow and result in a deficiency of mature blood cells. There are various types of MDS, and lenalidomide is approved for the type associated with a truncation of chromosome 5 known as deletion 5q MDS. In combination with dexamethasone, it has also been designated for the second-line treatment of multiple myeloma, a B cell malignancy characterized by excess monotypic plasma cells in the bone marrow. .

Chemical Properties

Yellow Solid

Originator

Celgene (US)

Uses

Immunomodulatory drug; analog of Thalidomide.

Uses

Lenalidomide (Revlimid, CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM.

Uses

Lovastatin content <1% 98%

Uses

A Thalidomide analog known to have immunomodulatory properties

Definition

ChEBI: A dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. Inhibits the secretion of TNF-alpha.

brand name

Revlimid(Celgene).

Biochem/physiol Actions

Lenalidomide, a derivative of thalidomide, is an immunomodulatory agent that is approved drug for treatment of multiple myeloma. Apparently Lenalidomide is a ligand of ubiquitin E3 ligase cereblon that induces the enzyme to degrade the Ikaros transcription factors IKAROS family zinc finger 1 (IKZF1) and IKZF3. Lenalidomide possess pleiotropic antitumor effects. It is used in the treatment of 5q-deletion associated myelodysplastic syndrome (del(5q)-MDS).

Lenalidomide Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Lenalidomide Suppliers

Novachemistry
Tel
44-20819178-90
Fax
(0)2080432064
Email
info@novachemistry.com
Country
United Kingdom
ProdList
4384
Advantage
58
More
Less

View Lastest Price from Lenalidomide manufacturers

WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD
Product
Lenalidomide 191732-72-6
Price
US $0.00/KG
Min. Order
100g
Purity
98%+
Supply Ability
100kg
Release date
2020-10-14
Hebei Crovell Biotech Co Ltd
Product
Lenalidomide 191732-72-6
Price
US $10.70/g/Bag
Min. Order
10g
Purity
99%
Supply Ability
10000kg
Release date
2021-07-02
Sinoway Industrial co., ltd.
Product
Lenalidomide 191732-72-6
Price
US $0.00/Kg/Bag
Min. Order
2Kg/Bag
Purity
98% up, USP / BP
Supply Ability
20tons
Release date
2021-07-12

191732-72-6, Lenalidomide Related Search:


  • enalidomide
  • Lenalidomid
  • Revlimid
  • 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione,Lenalidomide
  • LenalidoMide(CC-5013,RevliMid)
  • Lenalidomide ,98%
  • 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
  • 3-(4-aMino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
  • (3R)-3-(4-aMino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
  • LenalidoMide (RevliMid)
  • LenalidoMide (CC-5013)
  • LenalidoMide-d5
  • 3-(4-AMino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
  • (3S)-3-(4-amino-1-keto-isoindolin-2-yl)piperidine-2,6-quinone
  • (3S)-3-(4-amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione
  • (3S)-3-(4-amino-1-oxo-isoindolin-2-yl)piperidine-2,6-dione
  • (3S)-3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
  • enaL
  • idomide
  • CC-5013;CC5013;CC 5013
  • lenalidomide
  • 3-(7-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione
  • LenalidomideLenalidomide
  • 1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
  • 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione
  • CC-5013
  • Revlimi
  • Lenalidomide(other anti-cancers)
  • To the amine
  • Lenalidomide (This product is only available in Japan.)
  • 3-(4-Amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione
  • 3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
  • Leflunomidum
  • Lenalidomide USP/EP/BP
  • Lenadoamide
  • 99% purity Lenalidomide
  • Lenalidomide (Revlimid, CC5013)
  • 191732-72-6
  • 25926
  • Amines
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Inhibitor
  • CC-5013
  • Inhibitors
  • Molecular Targeted Antineoplastic
  • pharmaceutical intermediate
  • API